Recurrent rectal cancer
At least  but not more than  prior systemic therapies for advanced/recurrent or progressing disease.
Patients with recurrent disease or multiple primaries are ineligible
Patients with measurable recurrent disease of any previous substage (I-IV) are eligible to enrollment
Patients with recurrent disease may have received multiple prior chemotherapies for treatment of their uterine cancer
Can have recurrent disease from the primary disease (this is definition of oligorecurrent disease) but cannot have any other primary cancer diagnosed or treated within the last  years other than cutaneous skin cancer
Participants must have a biopsy-proven diagnosis of primary or recurrent gynecologic cancer for which intracavitary or interstitial brachytherapy is planned as standard treatment; eligible disease sites include primary or recurrent cancer of endometrial, ovarian, cervical, vaginal, or vulvar origin
Cohort B: Patients with recurrent endometrial cancer may have received up to  lines of cytotoxic chemotherapy (adjuvant and one line for recurrent disease, or  lines of chemotherapy for recurrent uterine cancer in patients who did not receive adjuvant chemotherapy); patients must have received and failed, or have been intolerant to platinum agents, taxanes, liposomal doxorubicin or other agents known to confer clinical benefit; patients are not required to fail all these agents if, in the investigators opinion, patients would benefit from treatment on current protocol
Recurrent or previously resected tumors
Recurrent breast cancer
Any episode of recurrent disease following completion of aggressive multi-drug frontline therapy.
recurrent/refractory disease after they received at least one prior standard treatment regimen
Part B: Must have a diagnosis of HR+ and HER- breast cancer; have locoregionally recurrent disease not amenable to resection or radiation therapy with curative intent or metastatic disease; no previous treatment or currently receiving  of the following treatments for locoregionally recurrent or metastatic breast cancer (chemotherapy, endocrine therapy, CDK/ inhibitor, and PIK and/or mTOR inhibitor)
No previous surgery for melanoma (other than complete macroscopic resection as stated above)(i.e. Not recurrent disease)
Participants with recurrent, progressive, or refractory brain tumors
Naive or recurrent patients with LG, non-invasive UTUC in the pyelocalyceal system.
Radiology evidence of reMB or recurrent grade III and IV glioma; patients will be considered for a biopsy or resection of the recurrent/progressive tumor at the discretion of the treating neurosurgeon and neuro-oncologist
Patients who need definitive radiotherapy for treatment of recurrent MB or recurrent grade III or IV glioma
Patients must have resistant/refractory or recurrent neuroblastoma
Recurrent or persistent histologically proven locoregional OCSCC (recurrent T-stage -) that was initially treated with surgery alone; to allow sufficient tumor tissue for the immunological analyses, patients with T-stage  OCSCC will be excluded
Patients must have advance, recurrent or metastatic endometrial cancer
Patients must have recurrent disease, histologically proven or imaging suggestive of recurrent disease as determined by principal investigator (PI); prior implantation of Gliadel wafers is acceptable, if tumor recurrence is confirmed by histologic examination of the recurrent tumor
Patients who already received chemotherapy for recurrent metastatic IBC are not eligible
Recurrent or progressive malignancy requiring anticancer treatment
Patients with recurrent endometrial cancer.
Recurrent or refractory disease according to NCI criteria
First episode of recurrent disease following completion of aggressive multi-drug frontline therapy.
Patients with macroscopic recurrent disease are allowed; macroscopic disease is defined as clinically detectable or evident on radiographic imaging
Patients must have progression of disease after radiotherapy (including patients that undergo surgery for recurrent disease and are rendered no evidence of disease [NED]); this includes recurrent glioblastoma multiforme (GBM) after receiving all standard first-line treatment, including surgery (if feasible due to neurosurgical and neuro-anatomical considerations) and adjuvant radiotherapy +/- chemotherapy
Subjects with recurrent disease
Recurrent disease with an:
In Stage , recurrent or metastatic PR-expressing cancer that has the potential to benefit from an anti-progestin treatment including but not limited to endometrial cancer, ovarian, or breast cancer or uterine sarcoma. In Stage , recurrent or metastatic PR-expression uterine endometrioid adenocarcinoma that is determined to be APRpos.
Subjects with confirmed diagnosis of recurrent or metastatic breast cancer based on histopathology examination
Metastatic or locoregionally recurrent HER-negative breast cancer; resectable disease allowed
Patients must have refractory, recurrent or metastatic disease, which is deemed to be inoperable
For expansion cohort: metastatic platinum-refractory cervical cancer, or metastatic/recurrent platinum-refractory HPV-positive head and neck cancer (as determined by polymerase chain reaction (PCR), in situ hybridization (ISH), or p immunohistochemistry (IHC); platinum refractory is defined as recurrent disease within  months after receiving cisplatin or carboplatin with radiation for their newly diagnosed disease, or after receiving cisplatin or carboplatin for their recurrent/metastatic disease
All patients must have recurrent or metastatic HER-positive breast cancer; diagnosed by biopsy
Progressive or recurrent breast cancer defined as disease progression or recurrence while on a combination of exemestane with everolimus
Patients who are to be given HDR brachytherapy for treatment of solid tumor of the following:\r\n* Gynecologic (primary cervix and recurrent cervix/uterine cancer)\r\n* Prostate (locally advanced/recurrent cancer)
Patients must have received at least one prior standard systemic therapy with documented recurrent or refractory disease
Patients may have received chemotherapy as a component of their primary tumor treatment but not for recurrent or metastatic disease
Patients with measurable recurrent disease of any previous substage (I-IV) are eligible to enrollment
Patients with recurrent disease may not have received more than three prior chemotherapies for treatment of their uterine cancer
Patients must have clinically evident recurrent disease for the purpose of this study
Patients whom have already undergone secondary cytoreduction for recurrent disease are excluded
Widespread (metastatic) disease, or returned after previous treatment (recurrent)
Previous treatment for metastatic or recurrent disease
Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting.
Patients who have undergone recent surgery for recurrent or progressive tumor are eligible provided that:
Patients with recurrent uterine LMS
Confirmed recurrent or metastatic disease
No prior systemic chemotherapy for recurrent or metastatic disease
Previous chemotherapy for recurrent or metastatic disease.
Patients with recurrent WHO grade III gliomas should have received one prior treatment for recurrent high grade disease
Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer
Patients must have confirmed Cushing's disease that is persistent or recurrent.
SCCHN that has progressed during or following at least  and up to  prior systemic treatments for metastatic or recurrent disease deemed to be incurable. Patient who refuse radical resection for recurrent disease or are intolerant of or refused standard first line therapy are eligible to enroll
Patients must have advanced or recurrent disease that is refractory to curative treatment based on imaging or clinical exam.
Patients must have had no more than two prior chemotherapeutic regimens for recurrent endometrial carcinoma. Chemotherapy administered in conjunction with primary radiation as a radio-sensitizer is not counted as a prior treatment for recurrent or advanced disease.
Patient must have recurrent epithelial ovarian cancer and may have received unlimited prior chemotherapeutic regimens for management of recurrent cancer
Histologically confirmed recurrent or metastatic SCCHN; tumor progression or recurrence during or after treatment with only  systemic palliative regimen for recurrent or metastatic disease that must have contained a platinum agent; Patients who have only received chemo-radiation with curative intent for treatment of their locally advanced disease or recurrent disease are not eligible. Patients who received concurrent chemo-radiation as part of treatment of their recurrent disease are also not eligible.
Received more than  regimen for recurrent or metastatic disease
Previously treated with  or more systemic regimens given for recurrent and/or metastatic disease
Presence of metastatic or recurrent disease
Received more than  systematic palliative regimen for recurrent or metastatic disease
Recurrent or persistent (after the failure of chemotherapy) disease that cannot be treated with surgery or radiotherapy;
Recurrent or refractory solid tumors
Locoregionally recurrent or metastatic disease that has not previously been treated with systemic therapy of recurrent or metastatic disease
Patients must have had no more than two prior chemotherapeutic regimens for recurrent management of endometrial carcinoma; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer is not counted as a prior treatment for recurrent or advanced disease
Subjects with recurrent breast cancer
Receiving any treatment for persistent, progressive or recurrent malignancy.
Progressive or recurrent malignancy defined other than by quantitative molecular assays.
Prior palliative chemotherapy for metastatic or recurrent disease
Prior biological therapy for metastatic or recurrent disease within  weeks prior to randomization
Patients with recurrent or refractory ESFT. Patients with de novo poor prognosis/high risk ESFT: (Eligible for vaccine manufacturing at diagnosis but ONLY ELIGIBLE FOR IMMUNOTHERAPY IF DEMONSTRATES PERSISTENT/RECURRENT/ REFRACTORY DISEASE)
Recurrent breast cancer
Has recurrent rectal or rectosigmoid cancer.
Patient treated with more than one prior chemotherapy regimen for recurrent/metastatic disease
History of histological confirmation for recurrent disease, or if recurrent disease is not readily accessible to biopsy, must have two consecutive carcinoembryonic antigen (CEA) or cancer antigen (CA) - increases, or positron emission tomography (PET) avidity
Recurrent disease with an:
interval of at least  weeks between end of surgery for recurrent disease and start of protocol therapy for patients who have undergone surgery for recurrent disease
Recurrent breast cancer or other malignancy
Recurrent disease or second primary lung cancer (only de novo IIIA disease allowed)
Subjects with recurrent disease
Persistent and/or recurrent cervical cancer o No CNS/spinal metastases
Any therapeutic regimen for treatment of recurrent tumor after first line treatment with surgery, radiation and temozolomide.
Any number of prior chemotherapy regimens for recurrent disease (Phase I); =<  chemotherapy or other non-antiangiogenic regimen for recurrent disease (Phase II)
Patients who have recurrent disease after having had one or more prior resections may be eligible, provided that they are not candidates for further curative resection.
Tumor progression or recurrence within  months of last dose of platinum therapy that was used to treat metastatic, persistent or recurrent cervical cancer
History of NSCLC treated with surgery and/or radiotherapy previously and disease has been cured or clinically no disease progression for more than  months, now isolated recurrent disease in lung parenchyma and without involvement of main bronchus, chest wall, hilar/mediastinal lymph nodes and critical mediastinal structures; biopsy of recurrent disease is recommended
Prior treatment with an EGFR inhibitor as part of a regimen for recurrent or metastatic SCCHN
Subjects with recurrent ovarian, fallopian tube or peritoneal cancer who have clinical or radiologic evidence of a complete or partial response or stable disease after completion of first-line chemotherapy for their recurrent disease and are not suitable for additional cytotoxic therapy are eligible. These subjects may have previously received a course of adjuvant chemotherapy earlier in their disease management as described in point one above. These subjects are eligible regardless of their CA- results. These subjects may have been in a clinical trial of an investigational therapy.
Subjects who have received more than one course of chemotherapy for recurrent disease
Phase I: Diagnosis of recurrent, metastatic or primary unresectable solid tumor that does not have curative standard treatment
Diagnosis: \r\n* Part A: Recurrent or refractory neuroblastoma or melanoma\r\n* Part B: Recurrent or refractory neuroblastoma or melanoma\r\n* Part C: Recurrent or refractory osteosarcoma and Ewing sarcoma
Patients with advanced or recurrent salivary gland cancer who are not candidates for curative surgery or radiotherapy.
Men and women with recurrent or advanced breast cancer
Women with of primary or recurrent diagnosis of ovarian, uterine, peritoneal, cervical or vulvar cancer with any of the following:\r\n* <  % projected  year survival based on histopathological stage\r\n* Non-pelvic recurrent malignancy\r\n* Persistent or progressive disease despite primary treatment with surgery, chemotherapy or\r\n* Palliative performance scale < 
Recurrent or persistent progressive disease which is refractory to curative therapy or established treatments and cannot be treated with surgery or radiotherapy;
Recurrent cancer following prior resection
First or recurrent presentations
Evidence of recurrent breast cancer at the time of enrollment
Recurrent or progressive malignancy requiring anti-cancer therapy
Patient has recurrent hyperparathyroidism
Recurrent or progressive malignancy requiring anticancer treatment
A diagnosis of advanced cancer (defined as metastatic or recurrent) with fatigue >= / (- scale) on the Edmonton Symptom Assessment Scale (ESAS)
Recurrent cancer
Recurrent disease
Subjects must have histologic documentation of advanced recurrent or metastatic cancer.
Recurrent cancer
Patients with evidence of recurrent malignancy
Recurrent breast cancer
Synovial sarcoma that has been treated with standard chemotherapy containing ifosfamide and/or doxorubicin and remains: unresectable or metastatic or progressive/persistent or recurrent disease
Recurrent tumors: patients with recurrent grade IV gliomas who have failed cranial radiation therapy
Patients with recurrent disease or a new primary will be allowed
Expected to undergo tumor tissue biopsy for known or suspected prostate cancer (in the primary, recurrent or metastatic disease setting)
Recurrent infratentorial tumor
Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :
Patients must have recurrent disease for which there is a clinical indication for resection
Any patient with recurrent or progressive cancer
No prior treatment with chemotherapy for a diagnosis of locoregionally recurrent or metastatic breast cancer is allowed.
Phase : Previous treatment with  or more systemic regimens given for recurrent and/or metastatic disease
